Novartis
Scotland starts newborn screening for SMA
March 26, 2026Novartis, Scotland, spinal muscular atrophy (SMA)
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will screen newborn babies for Spinal …
Novartis receives SMC approval for early breast cancer treatment
November 11, 2025Research and Development Novartis, Scottish Medicines Consortium, breast cancer, nhs scotland
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval for use within NHS Scotland …
Novartis candidate for Sjögren’s disease presents positive results
August 15, 2025Research and Development Immunology, Novartis, Sjögren’s disease, US Food and Drug Administration, clinical trial
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 – evaluating ianalumab in adults …
First malaria medicine for infants under 4.5kg receives approval
July 9, 2025Medical Communications, Research and Development Coartem Baby, Infections and infestations, Medicines for Malaria Venture, Novartis, Paediatrics, Swissmedic, malaria
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine for newborns and young infants. …
Novartis releases new data across oncology and haematology pipelines
May 21, 2025Research and Development ASCO, EHA, Haematology, Novartis, Oncology, oncology
Novartis has announced it will present new data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking …
PeptiDream and Novartis extend peptide discovery collaboration
April 30, 2024Research and Development Novartis, PeptiDream, Pharmacy, collaboration, drug discovery, peptides
PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.
Novartis shares new data about Fabhalta for IgAN treatment
April 16, 2024Research and Development Fabhalta, IgAN, Nephrology, Novartis, nephropathy
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN trial of Fabhalta (iptacopan), an …
Novartis shares new data for Zolgensma in children with SMA
March 5, 2024Musculo-skeletal disorder, Novartis, Zolgensma, sma, spinal muscular atrophy
Novartis has announced new data to continue the support of the clinical benefits of Zolgensma (onasmenogene abeparvovec), for the treatment …
Novartis to acquire MorphoSys AG for €2.7bn
February 6, 2024Business Services Novartis, Pharmacy, acquisition, morphosys
Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, or €68 per share. The …
Calypso Biotech to be acquired by Novartis for $250m
January 8, 2024Business Services Calypso Biotech, Immunology, Novartis, acquisition
Calypso Biotech has announced that it has entered into an agreement to be acquired by Novartis. The company’s shareholders will …
FDA approves Novartis’ Fabhalta for PNH treatment
December 6, 2023Medical Communications FDA, Fabhalta, Haematology, Novartis, PNH
Novartis has announced that the US Food and Drug Administration has approved Fabhalta (iptacopan) as the first oral monotherapy for …
Ionis and Novartis partner for CVD treatment programme
August 4, 2023Business Services Cardiology, Ionis Pharmaceuticals, License Agreement, Novartis, cvd
Ionis Pharmaceuticals has announced that it has entered into a new collaboration and license agreement with Novartis, aiming to discover, …
Novartis acquires Chinook Therapeutics for $3.5bn
June 12, 2023Mergers and Acquisitions Chinook Therapeutics, Nephrology, Novartis, kidney disease, pharma
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based biopharmaceutical company Chinook Therapeutics for …
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
April 27, 2023Business Services CHMP, Cosentyx, Dermatology, Novartis
Basel, April 26, 2023 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European …
AstraZeneca, Klarify, and Novartis Gene Therapies top Digital Awards leaderboard
September 20, 2021Sales and Marketing AstraZeneca, Klarify, Novartis, PM Society Awards, havas life medicom
Pharmaceutical companies AstraZeneca, Klarify, and Novartis Gene Therapies all received two gold awards at the 12th PM Society Digital Awards …
